Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa